1.0SwedenBIOhttps://swedenbio.se/en/Hansa Biopharma - SwedenBIOrich600338<blockquote class="wp-embedded-content" data-secret="1JAQfbFT0O"><a href="https://swedenbio.se/en/medlemmar/hansa-medical-ab/">Hansa Biopharma</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://swedenbio.se/en/medlemmar/hansa-medical-ab/embed/#?secret=1JAQfbFT0O" width="600" height="338" title="“Hansa Biopharma” — SwedenBIO" data-secret="1JAQfbFT0O" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script>
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://swedenbio.se/wp-includes/js/wp-embed.min.js
</script>
Hansa Biopharma envisions organ transplantations made available to sensitized patients and for swift inhibition of attacks by the immune system to be brought to patients suffering from autoimmune conditions. The company’s lead candidate drug, IdeS, is primarily developed as a single dose treatment to enable kidney transplantation for sensitized patients.